Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Oct 1;31(10):e96-e100.
doi: 10.1097/IJG.0000000000002048. Epub 2022 May 6.

Intraocular Peak Pressure in Patients Under Treatment With Fixed Combination of Bimatoprost/Timolol/Brimonidine Once Daily Versus Twice Daily

Bianca N Susanna  1 , Carolina N Susanna  1 , Fernanda N Susanna  2 , Rodrigo T Mota  1 , Gabriel C S Barbosa  3 , Vagner L Lima  1 , Remo Susanna Jr  2
Affiliations
Randomized Controlled Trial

Intraocular Peak Pressure in Patients Under Treatment With Fixed Combination of Bimatoprost/Timolol/Brimonidine Once Daily Versus Twice Daily

Bianca N Susanna et al. J Glaucoma. .

Abstract

Prcis: We investigate the efficacy of triple-fixed-combination of bimatoprost/brimonidine/timolol once and twice a day, demonstrating higher intraocular pressure reduction with once-a-day use, and discuss possible implications based on previous literature.

Purpose: The purpose of this study was to compare the efficacy of a fixed combination bimatoprost-timolol-brimonidine (Triplenex) instilled once-daily with twice-daily in primary open angle glaucoma.

Patients and methods: A randomized clinical trial at a public eye care institution. Thirty patients with primary open angle glaucoma were followed up for 3 months. The right and left eyes of these patients were randomly assigned to once-daily (10:00 pm ) or twice-daily (10:00 am ; 10:00 pm ) regimens of fixed combination bimatoprost-timolol-brimonidine. Intraocular pressure peaks were obtained with the water drinking test before the introduction of this medication (basal WDT0), 1 month (WDT1), 2 months (WDT2), and 3 months (WDT3) after starting the use of the fixed combination of bimatoprost/timolol/brimonidine (Triplenex). Variation from peak intraocular pressure at WDT3 to peak at WDT0 was compared within groups of 2 versus once-daily regimen.

Results: Sixty eyes of 30 patients (age: 70.67±9.70 y) were included in this study. Baseline clinical characteristics were comparable between groups. The mean reduction in peak intraocular pressure from WDT0 to WDT3 was 6.1±6.1 mm Hg (30.5%) in the eyes receiving 1 drop per day and 4.3±5.7 mm Hg (21.5%) in the eyes receiving 2 drops per day ( P =0.023). Mean reduction in peak intraocular pressure considering all WDT was also higher in the group with once-a-day treatment (5.90±6.03 vs. 4.46±4.28 mm Hg, P =0.006).

Conclusion: Fixed combination of bimatoprost 0.01%, brimonidine tartrate 0.15%, and timolol maleate 0.5% once-a-day is more effective in reducing peak intraocular pressure as measured by the WDT than twice-a-day dosing.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors declare no conflict of interest.

References

    1. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714–720.
    1. Hyman L, Heijl A, Leske MC, et al. Natural history of intraocular pressure in the early manifest glaucoma trial: a 6-year follow-up. Arch Ophthalmol. 2010;128:601–607.
    1. European Glaucoma Society. Terminology and Guidelines for Glaucoma, 4th Edition. The Guidelines project was entirely supported by the European Glaucoma Society Foundation; 2014.
    1. Djafari F, Lesk MR, Harasymowycz PJ, et al. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18:238–243.
    1. Belfort R Jr, Paula JS, Lopes Silva MJ, et al. Fixed-combination bimatoprost/brimonidine/timolol in glaucoma: a randomized, masked, controlled, phase III study conducted in Brazil. Clin Ther. 2020;42:263–275.

Publication types

LinkOut - more resources